nct05564169

Migration, Crosslink

📖

nct05564169

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct05564169

📖 Wiki Page

clinical_trial1795 wordssynced 2026-04-02

Masitinib Phase 3 Trial for Mild Alzheimer's Disease (NCT05564169)

Overview

flowchart TD clinical_trials_nct05564169["nct05564169"] style clinical_trials_nct05564169 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_0["Trial Details"] clinical_trials_nct05564169 -->|"includes"| clinical_trials_nct0_0 style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_nct0_1["Conditions Studied"] clinical_trials_nct05564169 -->|"includes"| clinical_trials_nct0_1 style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_nct0_2["Mechanism of Action"] clinical_trials_nct05564169 -->|"includes"| clinical_trials_nct0_2 style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_nct0_3["Tyrosine Kinase Inhibition"] clinical_trials_nct05564169 -->|"includes"| clinical_trials_nct0_3 style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_nct0_4["Multi-Target Anti-Inflammatory Effects"] clinical_trials_nct05564169 -->|"includes"| clinical_trials_nct0_4 style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_5["Rationale for Add-On Therapy"] clinical_trials_nct05564169 -->|"includes"| clinical_trials_nct0_5 style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

...

Masitinib Phase 3 Trial for Mild Alzheimer's Disease (NCT05564169)

Overview

Mermaid diagram (expand to render)

This pivotal Phase 3 clinical trial evaluates masitinib, a novel oral tyrosine kinase inhibitor, as an add-on therapy for patients with mild Alzheimer's disease. Masitinib represents a unique therapeutic approach that targets neuroinflammation through inhibition of key kinases involved in microglial activation and neuroinflammatory responses.

The trial is conducted by AB Science, a French pharmaceutical company that has been developing masitinib for various neurological conditions. This represents the most advanced clinical evaluation of masitinib in Alzheimer's disease and could establish a new treatment paradigm based on neuroinflammation modulation rather than direct amyloid or tau targeting["@masitinib2019"].

Alzheimer's disease affects approximately 55 million people worldwide, with the global burden projected to rise to 139 million by 2050. Despite significant advances in amyloid-targeting therapies, there remains a critical need for treatments that address the neuroinflammatory components of AD pathology that contribute to disease progression["@alzheimers2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05564169 |
| Phase | Phase 3 |
| Status | Not Yet Recruiting |
| Sponsor | AB Science |
| Enrollment | 600 participants |
| Enrollment Type | Estimated |
| Study Type | Interventional |
| Treatment | Masitinib (oral) + Standard of Care |
| Comparator | Placebo + Standard of Care |
| Start Date | June 2026 |
| Completion Date | December 2029 |
| Last Updated | October 3, 2025 |

Conditions Studied

Mild Alzheimer's Disease — defined as:
NIA-AA criteria for AD dementia
MMSE score of 21-26
Clinical Dementia Rating (CDR) global score of 0.5-1.0
On stable cholinesterase inhibitor and/or memantine therapy for ≥3 months

Mechanism of Action

Tyrosine Kinase Inhibition

Masitinib (AB Science, formerly known as AB1010) is an oral selective tyrosine kinase inhibitor that targets several kinases critical to neuroinflammation[@tnf2021]:

| Kinase | Role | Inhibition Effect |
|--------|------|-------------------|
| c-Kit | Mast cell survival and activation | Reduces mast cell-mediated inflammation |
| PDGFR | Microglial activation | Modulates neuroinflammatory responses |
| Lyn | Cell signaling in immune cells | Inhibits pro-inflammatory signaling |
| Fyn | Cell signaling in neurons | May provide neuroprotective effects |

Multi-Target Anti-Inflammatory Effects

Masitinib exerts its effects through multiple mechanisms[@neuroinflammation2022]:

Mast Cell Modulation: Masitinib inhibits c-Kit, which is essential for mast cell survival and function. Mast cells are resident immune cells in the brain that release pro-inflammatory mediators including histamine, TNF-alpha, and various proteases. By modulating mast cell activity, masitinib reduces the neuroinflammatory milieu.

Microglial Activation Suppression: The drug modulates microglial activation through PDGFR inhibition. Activated microglia release cytokines (IL-1β, IL-6, TNF-α) that drive neuroinflammation and contribute to synaptic dysfunction and neuronal loss.

TNF-Alpha Pathway Inhibition: TNF-alpha is a key pro-inflammatory cytokine elevated in AD brains. Masitinib reduces TNF-alpha production and signaling, addressing one of the central mediators of neuroinflammation.

Blood-Brain Barrier Interaction: While masitinib has moderate brain penetration, it exerts effects on peripheral immune cells that subsequently influence central nervous system inflammation through immune surveillance mechanisms.

Rationale for Add-On Therapy

The trial design as an add-on to standard of care (cholinesterase inhibitors and/or memantine) reflects a rational combination approach:

Complementary Mechanisms: Masitinib targets neuroinflammation while standard treatments provide symptomatic cognitive benefits
Established Safety Profile: Add-on design allows evaluation of masitinib in patients already receiving approved therapies
Clinical Relevance: Reflects real-world treatment paradigms where patients may receive multiple therapies

Study Design

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating masitinib as add-on therapy in mild AD patients receiving standard of care[@clinical2023].

Treatment Arms

| Arm | Treatment | Dose | Duration |
|-----|-----------|------|----------|
| 1 | Masitinib | 4.5 mg/kg/day (oral) | 24 weeks |
| 2 | Placebo | N/A | 24 weeks |

Note: Dose may be adjusted based on tolerability

Key Design Features

Add-On to Standard of Care: All participants continue receiving stable cholinesterase inhibitor (donepezil, rivastigmine, galantamine) and/or memantine therapy throughout the trial.

Mild Disease Focus: Enrollment limited to mild AD patients (MMSE 21-26), a population more likely to show measurable benefits from anti-inflammatory intervention.

24-Week Treatment Duration: Based on Phase 2 data showing treatment effects emerge within this timeframe.

Robust Outcome Measures: Multiple cognitive and functional assessments provide comprehensive efficacy evaluation.

Outcome Measures

Primary Endpoints

Change from baseline in the integrated Alzheimer's Disease Rating Scale (iADRS) at week 24

The iADRS is a composite score combining:

Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

This composite provides a comprehensive measure of both cognitive and functional domains.

Secondary Endpoints

Cognitive Measures:

Change in ADAS-Cog13 score
Change in Mini-Mental State Examination (MMSE)
Change in Montreal Cognitive Assessment (MoCA)

Functional Measures:

Change in ADCS-ADL
Change in Clinical Dementia Rating Sum of Boxes (CDR-SB)
Change in Disability Assessment for Dementia (DAD)

Behavioral Measures:

Change in Neuropsychiatric Inventory (NPI)
Change in Geriatric Depression Scale (GDS)

Biomarker Endpoints:

Change in cerebrospinal fluid (CSF) biomarkers (tau, p-tau, Aβ42)
Change in plasma inflammatory markers (TNF-α, IL-6)

Safety Endpoints:

Adverse events monitoring
Laboratory values
Electrocardiograms

Eligibility Criteria

Inclusion Criteria

Age ≥50 years

Diagnosis of probable AD according to NIA-AA criteria

MMSE score of 21-26

CDR global score of 0.5-1.0

On stable cholinesterase inhibitor and/or memantine therapy for ≥3 months

MRI or CT consistent with AD diagnosis

Able to provide informed consent (participant or caregiver)

Exclusion Criteria

Any cause of cognitive impairment other than AD

Significant psychiatric disorders (major depression, psychosis)

History of stroke or transient ischemic attack within 24 months

Significant cardiovascular, hepatic, or renal disease

Prior exposure to masitinib

Current use of immunosuppressive medications

Active malignancy or history of malignancy within 5 years

Clinical Significance

This Phase 3 trial represents a critical test of the neuroinflammation hypothesis in Alzheimer's disease. The outcomes of this study may[@future2024]:

Scientific Importance

Validate Neuroinflammation as Therapeutic Target: If successful, masitinib would provide first-in-class validation of tyrosine kinase inhibition for AD treatment.

Establish Add-On Treatment Paradigm: Demonstrating efficacy as add-on therapy would establish a new treatment combination approach.

Inform Inflammatory Biomarkers: Biomarker data will help identify which patients benefit most from anti-inflammatory treatment.

Clinical Impact

Oral Treatment Option: Unlike antibody therapies requiring infusions, masitinib is an oral medication, potentially improving patient access and convenience.

Disease Modification Potential: By targeting neuroinflammation, masitinib may slow disease progression rather than just providing symptomatic relief.

Combination with Other Mechanisms: Positive results would support development of combination regimens with amyloid-targeting therapies.

Regulatory Pathway

Masitinib has received Fast Track designation from the FDA for AD, which may expedite review if Phase 3 results are positive. The drug is already approved in Europe for mast cell tumors, providing a known safety profile.

Participating Sites

The trial will be conducted at multiple centers across Europe and potentially other regions:

| Country | Cities |
|---------|--------|
| France | Paris, Lille, Toulouse |
| Spain | Barcelona, Madrid, Granada, Donostia/San Sebastian, Albacete |
| Germany | Munich, Berlin, Hamburg |
| Italy | Milan, Rome, Florence |
| United Kingdom | London, Manchester |

Background and Preclinical Data

Phase 2 Results

A pivotal Phase 2 trial (NCT00988268) demonstrated masitinib's potential in AD[@masitinib2020]:

Primary Endpoint Met: Significant improvement in ADAS-Cog vs placebo (p=0.037)
Effect Size: Mean treatment difference of 2.8 points on ADAS-Cog
Population: Patients with mild-to-moderate AD (MMSE 12-24)
Safety: Generally well-tolerated with manageable adverse events

Key subgroup analyses showed:

Greatest benefit in patients with moderate disease (MMSE 12-19)
Significant improvement in behavioral symptoms (NPI)
Reduced caregiver burden

Preclinical Studies

Preclinical studies demonstrated:

Reduced microglial activation in AD mouse models
Decreased pro-inflammatory cytokine levels in brain tissue
Improved cognitive performance in transgenic AD mice
Neuroprotective effects against amyloid-beta toxicity

Mechanism Validation

Multiple lines of evidence support the neuroinflammation target:

Elevated cytokine levels (TNF-α, IL-1β, IL-6) in AD brain tissue
Correlation between neuroinflammation markers and disease severity
Genetic association between immune-related genes and AD risk
Mouse model studies showing benefit from anti-inflammatory interventions

Cross-Linking

[Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
[Microglial activation](/mechanisms/microglial-activation)
[Mast cell biology in CNS](/mechanisms/mast-cell-neuroinflammation)
[Cytokine-mediated toxicity](/mechanisms/cytokine-toxicity)

[TNF](/proteins/tnf-alpha)
[IL-6](/proteins/interleukin-6)
[c-Kit](/proteins/kit-receptor)
[APP](/proteins/app)

[Lecanemab CLARITY-AD](/clinical-trials/lecanemab-clarity-ad) — Amyloid-clearing antibody
[Donanemab TRAILBLAZER](/clinical-trials/dononemab-trailblazer) — Amyloid-clearing antibody
[Aduhelm](/clinical-trials/aduhelm) — First amyloid-targeting therapy

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
[Mastocytosis](/diseases/mastocytosis)

Challenges and Considerations

Patient Selection: Identifying patients most likely to benefit from anti-inflammatory treatment

Dose Optimization: Finding the optimal dose balancing efficacy and tolerability

Biomarker Development: Need for biomarkers predicting treatment response

Combination Safety: Ensuring safety when combined with cholinesterase inhibitors

Competition with Amyloid Therapies: Current amyloid-targeting antibodies have shown efficacy, creating high bar for new mechanisms

Current Status and Future Directions

As of the latest update, this Phase 3 trial is not yet recruiting, with enrollment expected to begin in June 2026.

This trial represents a critical test of the neuroinflammation modulation approach to Alzheimer's disease. Key questions the trial will address:

Does masitinib provide cognitive benefits in mild AD patients?
Is the treatment safe when added to standard AD medications?
Which patient subgroups benefit most from treatment?
Are there biomarker changes indicating disease modification?

If positive, masitinib could become the first approved anti-inflammatory treatment for AD, representing a fundamentally different approach than currently approved therapies. This would validate years of research into neuroinflammation as a central component of AD pathology and open new therapeutic avenues.

Even if the trial is negative, the results will contribute valuable information about the role of neuroinflammation in AD and help guide future development of anti-inflammatory strategies.

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT05564169)
[AB Science Pipeline](https://www.ab-science.com/)
[PubMed Search: Masitinib Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=masitinib+Alzheimer)

References

[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)

[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

[Masitinib for Alzheimer's disease: a randomized, double-blind, placebo-controlled phase 2 study (2019)](https://doi.org/10.1016/j.jalz.2019.01.001)

[Masitinib added to standard drug treatment in patients with mild Alzheimer's disease (2020)](https://doi.org/10.3233/JAD-190883)

[Neuroinflammation in Alzheimer's disease: mechanisms and therapeutic targets (2022)](https://doi.org/10.1038/s41582-022-00622-x)

[TNF-alpha as a therapeutic target in Alzheimer's disease (2021)](https://doi.org/10.1186/s12974-021-02109-w)

[Microglia in Alzheimer's disease: from pathogenesis to therapeutic modulation (2023)](https://doi.org/10.1016/j.cell.2023.03.005)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct05564169

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct05564169
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9dff3247fd2a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct05564169'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

23

Outgoing

27

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

nct05564169

Masitinib Phase 3 Trial for Mild Alzheimer's Disease (NCT05564169)

Overview

Masitinib Phase 3 Trial for Mild Alzheimer's Disease (NCT05564169)

Overview

Trial Details

Conditions Studied

Mechanism of Action

Tyrosine Kinase Inhibition

Multi-Target Anti-Inflammatory Effects

Rationale for Add-On Therapy

Study Design

Treatment Arms

Key Design Features

Outcome Measures

Primary Endpoints

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Clinical Significance

Scientific Importance

Clinical Impact

Regulatory Pathway

Participating Sites

Background and Preclinical Data

Phase 2 Results

Preclinical Studies

Mechanism Validation

Cross-Linking

Challenges and Considerations

Current Status and Future Directions

External Links

References

💬 Discussion

📗 Cite This Artifact

nct05564169

Masitinib Phase 3 Trial for Mild Alzheimer's Disease (NCT05564169)

Overview

Masitinib Phase 3 Trial for Mild Alzheimer's Disease (NCT05564169)

Overview

Trial Details

Conditions Studied

Mechanism of Action

Tyrosine Kinase Inhibition

Multi-Target Anti-Inflammatory Effects

Rationale for Add-On Therapy

Study Design

Treatment Arms

Key Design Features

Outcome Measures

Primary Endpoints

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Clinical Significance

Scientific Importance

Clinical Impact

Regulatory Pathway

Participating Sites

Background and Preclinical Data

Phase 2 Results

Preclinical Studies

Mechanism Validation

Cross-Linking

Related Mechanisms

Related Proteins/Genes

Related Clinical Trials

Related Diseases

Challenges and Considerations

Current Status and Future Directions

External Links

References

💬 Discussion